StockNews.AI
SPPI
StockNews.AI
13 days

Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors

1. Berger Montague is investigating SPPI for securities fraud claims. 2. False statements were allegedly made regarding the Pinnacle Study. 3. Shares of SPPI were delisted following a merger with Assertio Holdings. 4. Investors have until September 24, 2025, to seek lead plaintiff status. 5. The investigation targets investors who acquired SPPI shares between March and September 2022.

4m saved
Insight
Article

FAQ

Why Bearish?

The investigation raises concerns about transparency, similar to past fraud lawsuits that negatively affected stock prices.

How important is it?

The lawsuit directly impacts investor sentiment and could lead to financial repercussions for SPPI.

Why Long Term?

Long-term ramifications could occur if the lawsuit leads to significant financial penalties or loss of investor confidence, akin to other biotech firms facing similar actions.

Related Companies

ASRT
, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE. Spectrum is a biopharmaceutical company focused on oncology treatments. The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients. Spectrum shares were delisted following the Company's merger with Assertio Holdings, Inc. (NASDAQ: ASRT). If you are a Spectrum investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865. About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States. For more information or to discuss your rights, please contact:Andrew Abramowitz, Senior CounselBerger Montague(215) 875-3015[email protected] Caitlin AdorniBerger Montague(267) 764-4865[email protected]  SOURCE Berger Montague WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News